Ebola Vaccine Efficacious in Ring-Vaccination Trial in Guinea

One Ebola vaccine was highly efficacious in a trial conducted during an outbreak; another candidate vaccine showed strong but transient immunogenicity.

Investigators have reported the final results of an open-label, cluster-randomized, ring-vaccination trial using a recombinant, replication-competent, vesicular stomatitis virus–based candidate vaccine (rVSV-ZEBOV) that expresses a surface glycoprotein of Zaire Ebola virus. The trial was conducted during the Ebola epidemic. Clusters of contacts of Ebola cases were identified and randomly assigned to immediate vaccination or delayed vaccination (21 days later) with a single intramuscular dose of rVSV-ZEBOV. Other clusters of contacts were not randomized but were offered vaccination.

Among 2119 contacts in 51 clusters who consented to immediate vaccination, no cases of Ebola developed 10 days or more after randomization; among 2041 contacts in…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Ebola Vaccine Efficacious in Ring-Vaccination Trial in Guinea

Topics

Reviewing Author